Protagonist Short Term Debt from 2010 to 2024

PTGX Stock  USD 41.65  1.00  2.46%   
Protagonist Therapeutics Short Term Debt yearly trend continues to be fairly stable with very little volatility. Short Term Debt is likely to outpace its year average in 2024. During the period from 2010 to 2024, Protagonist Therapeutics Short Term Debt regression line of annual values had r-squared of  0.52 and arithmetic mean of  1,902,797. View All Fundamentals
 
Short Term Debt  
First Reported
2018-12-31
Previous Quarter
2.6 M
Current Value
45 K
Quarterly Volatility
696 K
 
Covid
Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 4.1 M or Selling General Administrative of 18 M, as well as many indicators such as Price To Sales Ratio of 20.61, Dividend Yield of 0.0 or PTB Ratio of 4.06. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagonist Therapeutics Correlation against competitors.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Latest Protagonist Therapeutics' Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Protagonist Therapeutics over the last few years. It is Protagonist Therapeutics' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagonist Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Protagonist Short Term Debt Regression Statistics

Arithmetic Mean1,902,797
Geometric Mean1,582,750
Coefficient Of Variation70.84
Mean Deviation1,096,396
Median1,061,000
Standard Deviation1,347,903
Sample Variance1.8T
Range4M
R-Value0.72
Mean Square Error940.7B
R-Squared0.52
Significance0
Slope217,177
Total Sum of Squares25.4T

Protagonist Short Term Debt History

20243.1 M
20232.3 M
2022M
20214.4 M
20202.9 M
20191.3 M

About Protagonist Therapeutics Financial Statements

Protagonist Therapeutics investors use historical fundamental indicators, such as Protagonist Therapeutics' Short Term Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Debt2.3 M3.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.